Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 176-181

  Ryan, Pablo ^a   Resino, Salvador ^b   Miralles, Pilar ^a   Cosín, Jaime ^a   López, Juan Carlos ^a   Moreno, Silvia ^b   Catalán, Pilar ^a   Ramírez, Margarita ^a   Gutiérrez, Isabel ^a   Berenguer, Juan ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

HCV; HIV; HIV HCV coinfection; Insulin resistance; Interferon plus ribavirin; Sustained virologic response

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FIBROSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; PRIORITY JOURNAL; COMPLICATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; VIRUS LOAD; WESTERN BLOTTING;

ADULT; ANTIVIRAL AGENTS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 77957320950     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e5b1f0     Document Type: Article

References (38)

1. Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004;99:636-644.
2. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
3. Berenguer J, Alvarez-Pellicer J, Miralles Mart́n P, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407-413.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358: 958-965.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-982.
6. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40: 993-999.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140: 346-355.
8. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357: 124-134.
9. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: A research synthesis. J Viral Hepat. 2007;14:239-248.
10. Dore GJ, Torriani FJ, Rodriguez-Torres M, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS. 2007;21:1555-1559.
11. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634-651.
12. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271.
13. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.
14. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008;47:35-42.
15. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954-960.
16. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006; 44:97-103.
17. Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS. 2007;21:477-481.
18. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat. 2007;14:228-238.
19. Martin-Carbonero L, Nunez M, Marino A, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS. 2008;22:15-21.
20. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-641.
21. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48:28-34.
22. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2007;30(Suppl 1):S42-S47.
23. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28: 412-419.
24. Ascaso JF, Romero P, Real JT, et al. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin (Barc). 2001;117:530-533.
25. Merchante N, Macias J, Ramayo E, et al. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C viruscoinfected patients. J Viral Hepat. 2006;13:449-456.
26. Ryan P, Berenguer J, Michelaud D, et al. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCVcoinfected patients. J Acquir Immune Defic Syndr. 2009;50:109-110.
27. Jacobs WH, Goldberg SB. Statement on outpatient percutaneous liver biopsy. Dig Dis Sci. 1989;34:322-323.
28. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15-20.
29. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
30. Allison ME, Wreghitt T, Palmer CR, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21:1135-1139.
31. Camma C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol. 2009;50: 648-651.
32. Cua IH, Hui JM, Kench JG, et al. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology. 2008; 48:723-731.
33. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125:1695-1704.
34. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738-744.
35. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743-1751.
36. Bongiovanni M, Ranieri R, Casana M, et al. Insulin resistance affects early virologic response in HIV-infected subjects treated for hepatitis C infection. J Acquir Immune Defic Syndr. 2008;47:258-259.
37. Nasta P, Gatti F, Puoti M, et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferonalfa- 2a. AIDS. 2008;22:857-861.
38. Merchante N, de los Santos-Gil I, Merino D, et al. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol. 2009;50:684-692.